tamibarotene has been researched along with Acute Myelogenous Leukemia in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Baker, K; Banos, A; Bixby, D; Braun, T; Carulli, J; Cluzeau, T; Cook, RJ; de Botton, S; Eaton, M; Fenaux, P; Fiore, C; Hodgson, G; Jurcic, JG; Kang-Fortner, Q; Kelly, MJ; Liesveld, JL; Madigan, K; McKeown, M; Paul, S; Rizzieri, DA; Roboz, GJ; Roth, DA; Rousselot, P; Savona, MR; Sekeres, MA; Stein, EM; Stephens, K; Vigil, C; Volkert, A | 1 |
| Koyama, T; Shinki, H; Tsunaka, M | 1 |
| Austgen, K; Chan, SM; Chen, MW; Corces, MR; Eaton, ML; Fiore, C; Fritz, CC; Guenther, MG; Koenig, JL; Lee, E; Lopez, JT; Lovén, J; Majeti, R; McKeown, MR; Orlando, DA; Smith, D | 1 |
| Ledford, H | 1 |
| Inamura, J; Kohgo, Y; Shindo, M | 1 |
| Takeshita, A | 1 |
2 review(s) available for tamibarotene and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
[Molecular target drugs for AML--current state and prospects for the future].
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Benzoates; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Tetrahydronaphthalenes; Tretinoin | 2014 |
[Recent advances in the treatment of acute myelogenous leukemia: a view of the new agents].
Topics: Alkyl and Aryl Transferases; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzoates; Cyclosporine; Cytarabine; Daunorubicin; Drug Design; Farnesyltranstransferase; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Nucleosides; Oxides; Prognosis; Radioisotopes; Remission Induction; Tetrahydronaphthalenes; Topoisomerase Inhibitors; Tretinoin; Verapamil | 2003 |
4 other study(ies) available for tamibarotene and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML.
Topics: Azacitidine; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Myelodysplastic Syndromes; Retinoic Acid Receptor alpha | 2023 |
Cell-based evaluation of changes in coagulation activity induced by antineoplastic drugs for the treatment of acute myeloid leukemia.
Topics: Antineoplastic Agents; Benzoates; Cell Line, Tumor; Cytarabine; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; Idarubicin; Leukemia, Myeloid, Acute; Phosphatidylserines; Tetrahydronaphthalenes; Thrombomodulin; Thromboplastin | 2017 |
Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist.
Topics: Aged; Animals; Benzoates; Cell Line, Tumor; Cell Proliferation; Cell Survival; Enhancer Elements, Genetic; Epigenomics; Female; Gene Expression Regulation, Neoplastic; High-Throughput Nucleotide Sequencing; Humans; Leukemia, Myeloid, Acute; Mice; Retinoic Acid Receptor alpha; Tetrahydronaphthalenes; Up-Regulation; Xenograft Model Antitumor Assays | 2017 |
Cancer researchers seek to harness mysterious DNA 'super-enhancers'.
Topics: Benzoates; Cell Differentiation; Clinical Trials as Topic; DNA, Neoplasm; Embryonic Stem Cells; Enhancer Elements, Genetic; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Neoplasms; Tetrahydronaphthalenes; Uncertainty | 2018 |